KeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
AbCellera Biologics Is Maintained at Overweight by Keybanc
AbCellera Biologics Is Maintained at Overweight by Keybanc
AbCellera Biologics Price Target Cut to $7.00/Share From $8.00 by Keybanc
AbCellera Biologics Price Target Cut to $7.00/Share From $8.00 by Keybanc
Keybanc: Maintaining the ABCellera Biologics (ABCL.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $8.00 to $7.00.
Keybanc: Maintaining the ABCellera Biologics (ABCL.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $8.00 to $7.00.
Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7
Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics with a Overweight and lowers the price target from $8 to $7.
AbCellera Biologics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 83.73% Keybanc $8 → $7 Maintains Overweight 02/22/2024 — Benchmark Upgrades Hold → Buy 02/21/2
Earnings Call Summary | AbCellera Biologics(ABCL.US) Q1 2024 Earnings Conference
The following is a summary of the AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript:Financial Performance:AbCellera reported Q1 2024 revenue of $10 million, primarily from research fees
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
Analysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)
AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates
AbCellera Biologics | 10-Q: Quarterly report
AbCellera Biologics Reviews Q1 Earnings With Corporate Presentation
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q1 Revenue $10M, Vs. Street Est of $10.9M
04:25 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q1 Revenue $10M, vs. Street Est of $10.9M
AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $9.954 m
Press Release: AbCellera Reports Q1 2024 Business Results
AbCellera Reports Q1 2024 Business Results VANCOUVER, British Columbia--(BUSINESS WIRE)--May 07, 2024-- AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All
AbCellera Partners With PE Firms to Develop Antibody Drugs, Company Creation
Institutional Owners May Consider Drastic Measures as AbCellera Biologics Inc.'s (NASDAQ:ABCL) Recent US$91m Drop Adds to Long-term Losses
Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
No Data